Page 2 - Best Leiomyosarkoma doctors: TOP 61 doctors

The doctor graduated from Ankara University Medical School and completed residency training in internal medicine at Ankara GATA Medical School. Specializing in medical oncology and hematology, the doctor completed a clinical fellowship in the USA. A pioneer in Turkey, the doctor was part of the team that performed the first bone marrow transplantation in the country. The doctor has served as a visiting lecturer at prestigious institutions in London and Switzerland. Holding the European Medical Oncology Certificate, the doctor is a founding member of both The Turkish Society of Medical Oncology and the Turkish Oncology Group. The clinical focus includes breast, gastrointestinal, lung cancers, lymphomas, and myeloma.

Dr. Tahsin Ozadli specializes in medical oncology with extensive training at Ankara Oncology Hospital.

• Specialized in lung, esophageal, and gastric cancers
• Worked at Ankara Oncology Hospital's Medical Oncology Clinic
• Published research in oncology – see Google Scholar profile

Professor Keil specializes in cross-sectional imaging and interventional radiology, applying advanced techniques like MRI, CT, and ultrasound for precise diagnostic and treatment planning.

• Graduated with honors from Julius-Maximilians-Universität Würzburg
• Led the Diagnostic and Interventional Radiology Clinic at University Hospital of Aachen
• Currently Chief Physician at Academic Hospital Solingen
• Expert in MRI and CT for complex disease patterns

Prof. Elke Jaeger heads Oncology and Hematology at Nordwest – named one of Germany's best oncologists by Focus.

• 41 years of experience of experience specializing in oncology
• Performed 1,100+ procedures
• Professor of Interdisciplinary Oncology
• Member of the EORTC expert committee

Dr. Levin leads the pediatric sarcoma program at Sourasky Medical Center and studied at Italy's world-leading Rizzoli Orthopaedic Institute.

• Over 41 years of experience of experience in pediatric hematology and oncology
• Specializes in bone tumors and soft tissue sarcoma in children
• Senior pediatrician at Dana Children's Hospital in Tel Aviv
• Director of the pediatric hematology-oncology department at Sourasky
• Member of the Israeli Society of Pediatric Hematology Oncology

Prof. Dr. Ozcan Yildiz has over a decade of specialized research and publication in complex oncology cases. He treats patients at Medipol Mega University Hospital.

• Author of numerous studies on rare tumors like neuroendocrine and neuroectodermal cancers
• Expertise includes handling cancer-related paraneoplastic syndromes and unusual presentations
• Experienced in managing complex side effects from advanced cancer therapies
• Member of professional oncology research networks, contributing to medical literature

Prof. Köstler is a distinguished medical oncologist specializing in targeted therapies, with over 22 years of experience of experience in breast and gynecologic cancers at Wiener Privatklinik.

• Associate Professor at Medical University of Vienna
• Deputy Head of Clinical Division of Oncology
• Expert in biomarker development and tumor biology
• Published in leading international oncology journals

Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.

He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.

Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.

Dr. Alemdar specializes in medical oncology with extensive training at Akdeniz University, a leading institution in Turkey.

• Board-certified in medical oncology since 2018
• Over 20 years of experience of experience in internal medicine and oncology
• Worked at Akdeniz University Hospital, known for its advanced cancer treatments

Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.

Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).

Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).

Dr. Mariam Mohammed Hussein Abu Zeid is a clinical oncologist. She treats solid tumors and hematologic cancers. She earned her MBBCh from Ain Shams University in 2007 (Excellent). She completed a Master’s in Clinical Oncology and Nuclear Medicine in 2011 (Very Good). She received a Ph.D. in 2018 and an ESMO Certificate in 2015.

She leads and monitors clinical trials. Her work includes data collection and analysis. She administers chemotherapy and manages treatment toxicities. She also plans care with multidisciplinary teams. Her experience includes Ain Shams University Hospitals (2009–2012), the International Medical Center (2012–2014), and Wadi El Nile Hospital (2015–2019). Her roles covered diagnosis and staging, supportive care, quality improvement, and screening. She educates patients and families about the diagnosis, treatment options, and palliative care.

Assoc. Prof. Nail Paksoy specializes in Leiomyosarkoma at Medipol Bahcelievler Hospital, with ESMO Board Certification in Medical Oncology.

• Published research on high-dose chemotherapy for Ewing's Sarcoma
• Subinvestigator in 8 international clinical trials for advanced cancers
• Medical Oncology fellowship at Istanbul University Oncology Institute
• Member of ESMO with expertise in sarcoma treatments

Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.

He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.

His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.

49 years of experience in immunology – Dr. Jaunalksne specializes in virotherapy, a cutting-edge approach to immune system modulation.

• Head of Clinical Immunology Center at Pauls Stradins Clinical University Hospital
• Graduate of Riga Medical Institute with internship in Internal Medicine
• Focuses on innovative immunology treatments

Dr. Emad Shash, M.B.B.Ch, MSc, M.D., is a medical oncologist. He is the Medical Director of the Breast Comprehensive Cancer Hospital at NCI. He leads the Medical Oncology Department and is the Breast Program Director at Shifaa Al Orman Cancer Hospital in Luxor. His clinical focus includes breast, gynecologic, genitourinary, thoracic, gastrointestinal, and rare cancers. He specializes in systemic therapy, including chemotherapy, targeted therapy, and immunotherapy.

He served as coordinating research physician and medical lead at the EORTC from 2011 to 2015. Since 2008, he has contributed to more than 70 international oncology trials as a coordinator, sub-investigator, principal investigator, and sponsor medical monitor. Credentials include M.B.B.Ch (2004), MSc (2010), MD (2015), and the EORTC Certificate of Excellence (2015). He also holds a Diploma in Hospital Quality Management & Patient Safety (JCI/57357, 2017). He is a Fellow of the EIO. He is a member of ESMO (panel voting), ESGO, and ASCO (IAC), and serves on the ECRIN board.

Dr. Mohamed Mahmoud Abdelhakim is Head of Radiation Oncology at Shefa al Orman Hospital, Luxor. He is Professor of Radiation Oncology at the National Cancer Institute, Cairo University. He previously served as Associate Professor (2015–2020), Lecturer (2010–2015), Assistant Lecturer (2003–2009), and Resident (2000–2003). He also worked as a Specialist at Gharbia Cancer Society.

He treats inpatients and outpatients with breast, soft tissue sarcoma, lymphoma, gynecologic, gastrointestinal, genitourinary, and CNS tumors. His skills include image-guided brachytherapy, IMRT, VMAT, SRS, and SBRT. He performs conventional and CT-based planning and 3D-CRT. He works with cobalt and linear accelerators and electron beam therapy. He provides HDR and LDR intracavitary and interstitial brachytherapy. He also performs stereotactic radiotherapy, total body irradiation, and total skin irradiation.

Member: Egyptian Cancer Society, ESTRO, ESMO.

Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).

He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.

Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.

Dr. Zohar Dotan is Head of the Urology Department at Sheba Medical Center. He is a leading uro-oncologist and a pioneer of robotic and laparoscopic urologic surgery in Israel.

He has authored more than 50 scientific publications. He is a regular speaker at international conferences. He has received awards from the American Association of Clinical Surgery, including recognition for research in prostate cancer treatment.

Leadership and credentials: Head of the Israeli Uro-Oncology Society. Assistant Professor at Tel Aviv University. Member of the Israeli, American, and European Urological Associations. Training: MD from Tel Aviv University and a PhD in Genetics. Urology residency at Sheba Medical Center. Fellowship in uro-oncology and laparoscopic surgery at Memorial Sloan Kettering, New York.

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.